87
Participants
Start Date
October 31, 2016
Primary Completion Date
March 26, 2019
Study Completion Date
March 26, 2019
INCAGN01949
Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
University Hospital of Laussane (CHUV), Lausanne
New York University Clinical Cancer Center, New York
Vanderbilt University Medical Center, Nashville
MD Anderson Cancer Center, Houston
Rutgers, The State University of New Jersey, New Brunswick
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
University College Hospital, London
University of Oxford, Oxford
Lead Sponsor
Incyte Biosciences International Sàrl
INDUSTRY